Download presentation
Presentation is loading. Please wait.
Published by霈漩 韦 Modified over 4 years ago
1
Fig. 1. CAR4 and CAR8 cells demonstrate in vitro and in vivo antileukemic efficacy.
CAR4 and CAR8 cells demonstrate in vitro and in vivo antileukemic efficacy. (A) In vitro killing of CD19+ murine ALL after 4 hours of coincubation, as measured by caspase 3/7 expression and loss of viable leukemia cells. E/T ratio, effector-to-target ratio. (B) Cytokine production of three biological replicates of CAR4 and CAR8 cells after 4 hours of coincubation with CD19+ ALL (error, SD; *P < 0.05, **P < 0.01, ****P < 0.001). (C) Survival analysis of syngeneic mice after infusion of 1 × 106 CAR4 or CAR8 or 5 × 105 CAR4 + 5 × 105 CAR8 cells 4 days after CD19+ ALL inoculation (n = 5 per group; P < , Mantel-Cox test). (D and E) Persistence of murine CAR4 and CAR8 cells in the bone marrow of syngeneic recipients 14 days after infusion of CAR4, CAR8, or mixed cells [n = 3; **P < 0.01, one-way analysis of variance (ANOVA) performed for all comparisons and log-rank Mantel-Cox test for survival analysis]. ns, not significant. Yinmeng Yang et al., Sci Transl Med 2017;9:eaag1209 Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.